monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $640 million.
Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $19.8 million for a PIV vaccine.
If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $20,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $38,000. If only 10% of primiparas utilized the vaccine, the annualized present value of the cost per QALY gained is $50,000.
Hall CB. Parainfluenza Viruses. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1613–1624.
Henrickson K, Ray R, Belshe R. Parainfluenza Viruses. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1489–1496.
Karron RA, Wright PF, Newman FK, et al. A Live Human Parainfluenza Type 3 Virus Vaccine is Attenuated and Immunogenic in Healthy Infants and Children. The Journal of Infectious Diseases 1995; 172:1445–1450.
Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.